These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30633110)

  • 21. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.
    Paul S; Del Tedesco E; Marotte H; Rinaudo-Gaujous M; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Roblin X
    Inflamm Bowel Dis; 2013 Nov; 19(12):2568-76. PubMed ID: 24013361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Which PCDAI Version Best Reflects Intestinal Inflammation in Pediatric Crohn Disease?
    Turner D; Levine A; Walters TD; Focht G; Otley A; López VN; Koletzko S; Baldassano R; Mack D; Hyams J; Griffiths AM
    J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):254-260. PubMed ID: 27050050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Associations Among Mucosal and Transmural Healing and Fecal Level of Calprotectin in Children With Crohn's Disease.
    Weinstein-Nakar I; Focht G; Church P; Walters TD; Abitbol G; Anupindi S; Berteloot L; Hulst JM; Ruemmele F; Lemberg DA; Leach ST; Cytter R; Greer ML; Griffiths AM; Turner D;
    Clin Gastroenterol Hepatol; 2018 Jul; 16(7):1089-1097.e4. PubMed ID: 29501599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn's disease.
    E Penna FGC; Rosa RM; da Cunha PFS; de Souza SCS; de Abreu Ferrari ML
    BMC Gastroenterol; 2020 Feb; 20(1):35. PubMed ID: 32054445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
    Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
    Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy.
    Ferreiro-Iglesias R; Barreiro-de Acosta M; Otero Santiago M; Lorenzo Gonzalez A; Alonso de la Peña C; Benitez Estevez AJ; Dominguez-Muñoz JE
    J Clin Gastroenterol; 2016 Feb; 50(2):147-51. PubMed ID: 25811118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial.
    Jongsma MME; Aardoom MA; Cozijnsen MA; van Pieterson M; de Meij T; Groeneweg M; Norbruis OF; Wolters VM; van Wering HM; Hojsak I; Kolho KL; Hummel T; Stapelbroek J; van der Feen C; van Rheenen PF; van Wijk MP; Teklenburg-Roord STA; Schreurs MWJ; Rizopoulos D; Doukas M; Escher JC; Samsom JN; de Ridder L
    Gut; 2022 Jan; 71(1):34-42. PubMed ID: 33384335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases.
    Ungar B; Glidai Y; Yavzori M; Picard O; Fudim E; Lahad A; Haberman Y; Shouval DS; Weintraub I; Eliakim R; Ben-Horin S; Weiss B
    J Pediatr Gastroenterol Nutr; 2018 Oct; 67(4):507-512. PubMed ID: 29901557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Matrix Metalloproteinase 3 Predicts Therapeutic Response in Inflammatory Bowel Disease Patients Treated With Infliximab.
    Barberio B; D'Incà R; Facchin S; Dalla Gasperina M; Fohom Tagne CA; Cardin R; Ghisa M; Lorenzon G; Marinelli C; Savarino EV; Zingone F
    Inflamm Bowel Dis; 2020 Apr; 26(5):756-763. PubMed ID: 31504536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fecal Calprotectin Levels Predict Histological Healing in Ulcerative Colitis.
    Patel A; Panchal H; Dubinsky MC
    Inflamm Bowel Dis; 2017 Sep; 23(9):1600-1604. PubMed ID: 28590341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Accuracy of a Home-performed Faecal Calprotectin Test in Paediatric Patients With Inflammatory Bowel Disease.
    Lerchova T; Hradsky O; Copova I; Potuznikova K; Gonsorcikova L; Bronsky J
    J Pediatr Gastroenterol Nutr; 2019 Jul; 69(1):75-81. PubMed ID: 30908389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fecal Calprotectin Levels Are Closely Correlated with the Absence of Relevant Mucosal Lesions in Postoperative Crohn's Disease.
    Garcia-Planella E; Mañosa M; Cabré E; Marín L; Gordillo J; Zabana Y; Boix J; Sáinz S; Domènech E
    Inflamm Bowel Dis; 2016 Dec; 22(12):2879-2885. PubMed ID: 27824646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn's disease patients.
    Foster AJ; Smyth M; Lakhani A; Jung B; Brant RF; Jacobson K
    World J Gastroenterol; 2019 Mar; 25(10):1266-1277. PubMed ID: 30886509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fecal calprotectin is not superior to serum C-reactive protein or the Harvey-Bradshaw index in predicting postoperative endoscopic recurrence in Crohn's disease.
    Verdejo C; Hervías D; Roncero Ó; Arias Á; Bouhmidi A; Lorente R; Salueña I; Lucendo AJ
    Eur J Gastroenterol Hepatol; 2018 Dec; 30(12):1521-1527. PubMed ID: 30303822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Higher Serum Infliximab Concentrations Following Subcutaneous Dosing are Associated with Deep Remission in Patients with Inflammatory Bowel Disease.
    Roblin X; Nancey S; Papamichael K; Duru G; Flamand M; Kwiatek S; Cheifetz A; Fabien N; Barrau M; Paul S
    J Crohns Colitis; 2024 May; 18(5):679-685. PubMed ID: 37934041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fecal Calprotectin Thresholds to Predict Endoscopic Remission Using Advanced Optical Enhancement Techniques and Histological Remission in IBD Patients.
    Cannatelli R; Bazarova A; Zardo D; Nardone OM; Shivaji U; Smith SCL; Gkoutos G; Ricci C; Gui XS; Ghosh S; Iacucci M
    Inflamm Bowel Dis; 2021 Apr; 27(5):647-654. PubMed ID: 32592477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fecal calprotectin is a strong predictive marker of relapse in Chinese patients with Crohn's disease: a two-year prospective study.
    Ye L; Chen BQ; Wang SD; Shi H; Yang Z; Wang FY
    Scand J Gastroenterol; 2017 Oct; 52(10):1113-1119. PubMed ID: 28675068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trefoil factor-3 is not a useful marker of mucosal healing in Crohn's disease treated with anti-TNF-α antibodies.
    Eder P; Stawczyk-Eder K; Korybalska K; Czepulis N; Luczak J; Lykowska-Szuber L; Krela-Kazmierczak I; Linke K; Witowski J
    World J Gastroenterol; 2017 Jan; 23(1):135-140. PubMed ID: 28104989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.